CLVSQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CLVSQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
Clovis Oncology's adjusted revenue per share for the three months ended in Sep. 2022 was $0.212. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.49 for the trailing ten years ended in Sep. 2022.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.
As of today (2024-04-27), Clovis Oncology's current stock price is $0.015. Clovis Oncology's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2022 was $0.49. Clovis Oncology's Cyclically Adjusted PS Ratio of today is 0.03.
The historical data trend for Clovis Oncology's Cyclically Adjusted Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clovis Oncology Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Cyclically Adjusted Revenue per Share | Get a 7-Day Free Trial | 1.85 | 1.13 | 0.85 | 0.76 | 0.49 |
For the Biotechnology subindustry, Clovis Oncology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Clovis Oncology's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Clovis Oncology's Cyclically Adjusted PS Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?
Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.
We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Clovis Oncology's adjusted Revenue per Share data for the three months ended in Sep. 2022 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Sep. 2022 (Change) | * | Current CPI (Sep. 2022) |
= | 0.212 | / | 125.2265 | * | 125.2265 | |
= | 0.212 |
Current CPI (Sep. 2022) = 125.2265.
Clovis Oncology Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201212 | 0.000 | 96.871 | 0.000 |
201303 | 0.000 | 98.209 | 0.000 |
201306 | 0.000 | 98.518 | 0.000 |
201309 | 0.000 | 98.790 | 0.000 |
201312 | 0.000 | 98.326 | 0.000 |
201403 | 0.403 | 99.695 | 0.506 |
201406 | 0.000 | 100.560 | 0.000 |
201409 | 0.000 | 100.428 | 0.000 |
201412 | 0.000 | 99.070 | 0.000 |
201503 | 0.000 | 99.621 | 0.000 |
201506 | 0.000 | 100.684 | 0.000 |
201509 | 0.000 | 100.392 | 0.000 |
201512 | 0.000 | 99.792 | 0.000 |
201603 | 0.000 | 100.470 | 0.000 |
201606 | 0.000 | 101.688 | 0.000 |
201609 | 0.000 | 101.861 | 0.000 |
201612 | 0.002 | 101.863 | 0.002 |
201703 | 0.160 | 102.862 | 0.195 |
201706 | 0.324 | 103.349 | 0.393 |
201709 | 0.344 | 104.136 | 0.414 |
201712 | 0.341 | 104.011 | 0.411 |
201803 | 0.366 | 105.290 | 0.435 |
201806 | 0.455 | 106.317 | 0.536 |
201809 | 0.432 | 106.507 | 0.508 |
201812 | 0.576 | 105.998 | 0.680 |
201903 | 0.626 | 107.251 | 0.731 |
201906 | 0.622 | 108.070 | 0.721 |
201909 | 0.687 | 108.329 | 0.794 |
201912 | 0.717 | 108.420 | 0.828 |
202003 | 0.594 | 108.902 | 0.683 |
202006 | 0.496 | 108.767 | 0.571 |
202009 | 0.439 | 109.815 | 0.501 |
202012 | 0.447 | 109.897 | 0.509 |
202103 | 0.365 | 111.754 | 0.409 |
202106 | 0.339 | 114.631 | 0.370 |
202109 | 0.313 | 115.734 | 0.339 |
202112 | 0.281 | 117.630 | 0.299 |
202203 | 0.248 | 121.301 | 0.256 |
202206 | 0.223 | 125.017 | 0.223 |
202209 | 0.212 | 125.227 | 0.212 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.
For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Clovis Oncology's Cyclically Adjusted PS Ratio of today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 0.015 | / | 0.49 | |
= | 0.03 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.
Thank you for viewing the detailed overview of Clovis Oncology's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas C. Harding | officer: See Remarks | 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301 |
Gillian C Ivers-read | officer: See Remarks | C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301 |
Lindsey Rolfe | officer: See remarks | C/O CLOVIS ONCOLOGY, INC., 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158 |
Daniel W Muehl | officer: See remarks | 5 BILLERICA PARK, 101 BILLERICA AVE, NORTH BILLERCA MA 01862 |
Paul Edward Gross | officer: See Remarks | 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80302 |
Ronit Simantov | director | 1988 CHAPEL STREET, NEW HAVEN CT 06515 |
James C Blair | director | 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204 |
Patrick J Mahaffy | director, officer: President and CEO | C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301 |
Thorlef Spickschen | director | TRAUBENWEG 25, 64342 SEEHEIN-JUGENHEIM 2M 00000 |
Richard A. Fair | director | C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030 |
Robert Azelby | director | 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109 |
Hooks Corwin Dale | officer: See remarks | C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, BOULDER CO 80301 |
Paul H Klingenstein | director | 428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301 |
Ginger L Graham | director | AMYLIN PHARMACEUTICALS, INC., 885 ARAPAHOE AVENUE, BOULDER CO 80302 |
Brian G Atwood | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
From GuruFocus
By Business Wire Business Wire • 12-09-2021
By Business Wire Business Wire • 01-10-2022
By Business Wire Business Wire • 05-05-2022
By Business Wire Business Wire • 04-28-2022
By Business Wire Business Wire • 10-27-2022
By Barry Cohen • 08-30-2021
By Business Wire Business Wire • 02-25-2022
By Business Wire Business Wire • 04-08-2022
By Business Wire Business Wire • 09-20-2021
By PRNewswire PRNewswire • 11-15-2022